Replimune Group, Inc. REPL | NASDAQ
|2026-09-10
Company Overview:
8.3 Year REPL Performance Metrics:
Build Custom Charts
REPL Financials: Earnings, Revenue, Cash Flow, Ebitda, Cash/Debt, Shares Float, etc:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for REPL
Based on past 8.3-year performance, here are REPL growth metrics:
Share price CAGR of +4.62%
Dividend CAGR of +0%
Using REPL CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| REPL (DRIP) | REPL - No DRIP | |
|---|---|---|
| Current Price | $22.05 | $22.05 |
| Start Shares | 453.51 | 453.51 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 453.51 | 453.51 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $22.05 | $22.05 |
| Total Dividends | $0 | $0 |
| Final Value | $10,000 | $10,000 |
NOTE: Above numbers are our estimate based on REPL's Dividend and Price CAGR over past 8.3 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Company Info
Replimune Group, Inc. (REPL) had its IPO on , and is traded on NASDAQ stock exchange.
Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its current work centers on engineered viral-based treatments designed to infect and destroy tumor cells while also stimulating an immune response against solid tumors. The company’s product pipeline includes therapies built on its proprietary RPx platform, with candidates aimed at multiple cancer settings. Replimune Group, Inc. serves the oncology market by advancing biologic approaches intended to complement or expand existing cancer treatment options. Headquartered in Woburn, Massachusetts, and founded in 2015, the company operates in the United States and the United Kingdom, with an emphasis on research, development, and commercialization of cancer immunotherapy programs.
REPL website: https://www.replimune.com
DCF model unavailable for REPL — no fundamentals on file (ETFs and funds are not modelable).
